Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could reusing your own blood after bypass cut donor transfusions?

NCT ID NCT06824753

Disease control Sponsor: Ataturk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving patients their own blood left over in the heart-lung machine after bypass surgery could reduce the need for donor red blood cell transfusions. Sixty adults having elective coronary bypass were split into two groups: one received the leftover blood, the other did not. Researchers tracked how many donor blood units each group needed and checked blood clotting with a special device.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous blood from the heart-lung machine
What this could lead to
If it works, this could reduce the need for donor blood transfusions after heart bypass surgery, lowering risks and conserving blood supplies.
What could go wrong
This is a small, single-center study with only 60 patients. The results may not apply to all heart surgery patients, and the approach may not significantly change transfusion needs or outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Apr 2023

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Elective cardiopulmonary bypass surgery 2. Ages 18-70 Exclusion Criteria: 1. Patients not accepting to be included in the study 2. Having kidney disease 3. Having hematological disease 4. Having peripheral artery disease 3- Ejection Fraction \< 45% 4- Anticoagulants usage

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardio-pulmonary bypass are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardio-pulmonary bypass

Contacts and locations

Locations

  • Ataturk University

    Erzurum, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.